StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note published on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Stock Down 7.2 %

Evogene stock opened at $1.67 on Tuesday. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40. The stock has a market cap of $8.97 million, a P/E ratio of -0.37 and a beta of 1.30. The company’s fifty day simple moving average is $1.60 and its 200-day simple moving average is $2.83.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.